Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

NCT06083454 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped funding change

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Pharmacological ascorbate
PROCEDURE: Surgery (SOC)

Sponsor

William Zeitler